{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T08:18:20Z","timestamp":1776759500345,"version":"3.51.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T00:00:00Z","timestamp":1714694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Community Behavioral Health, United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Audit and feedback (A\/F), which include initiatives like report cards, have an inconsistent impact on clinicians\u2019 prescribing behavior. This may be attributable to their focus on aggregate prescribing measures, a one-size-fits-all approach, and the fact that A\/F initiatives rarely engage with the clinicians they target.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, we describe the development and delivery of a report card that summarized antipsychotic prescribing to publicly-insured youth in Philadelphia, which was introduced by a Medicaid managed care organization in 2020. In addition to measuring aggregate prescribing behavior, the report card included different elements of care plans, including whether youth were receiving polypharmacy, proper medication management, and the concurrent use of behavioral health outpatient services. The A\/F initiative elicited feedback from clinicians, which we refer to as an \"audit and feedback loop.\" We also evaluate the impact of the report card by comparing pre-post differences in prescribing measures for clinicians who received the report card with a group of clinicians who did not receive the report card.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Report cards indicated that many youth who were prescribed antipsychotics were not receiving proper medication management or using behavioral health outpatient services alongside the antipsychotic prescription, but that polypharmacy was rare. In their feedback, clinicians who received report cards cited several challenges related to antipsychotic prescribing, such as the logistical difficulties of entering lab orders and family members\u2019 hesitancy to change care plans. The impact of the report card was mixed: there was a modest reduction in the share of youth receiving polypharmacy following the receipt of the report card, while other measures did not change. However, we documented a large reduction in the number of youth with one or more antipsychotic prescription fill among clinicians who received a report card.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A\/F initiatives are a common approach to improving the quality of care, and often target specific practices such as antipsychotic prescribing. Report cards are a low-cost and feasible intervention but there is room for quality improvement, such as adding measures that track medication management or eliciting feedback from clinicians who receive report cards. To ensure that the benefits of antipsychotic prescribing outweigh its risks, it is important to promote quality and safety of antipsychotic prescribing within a broader care plan.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-024-11029-5","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:02:24Z","timestamp":1714730544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Incorporating clinician insight and care plans into an audit and feedback initiative for antipsychotic prescribing to Medicaid-enrolled youth in Philadelphia"],"prefix":"10.1186","volume":"24","author":[{"given":"Molly","family":"Candon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen","family":"Rothbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abigail","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mia","family":"Everett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Demp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Weingartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oluwatoyin","family":"Fadeyibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,3]]},"reference":[{"key":"11029_CR1","doi-asserted-by":"crossref","unstructured":"Crystal S, Olfson M, Huang C, Pincus H, Gerhard T. Broadened Use of Atypical Antipsychotics; Safety, Effectiveness, and Policy Challenges. Health Aff. 2009;28(1):w770\u2013781.","DOI":"10.1377\/hlthaff.28.5.w770"},{"issue":"3","key":"11029_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1089\/cap.2013.0094","volume":"24","author":"M Burcu","year":"2014","unstructured":"Burcu M, Zito JM, Ibe A, Safer DJ. Atypical antipsychotic use among Medicaid-insured children and adolescents: duration, safety, and monitoring implications. J Child Adolesc Psychopharmacol. 2014;24(3):112\u20139.","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"5","key":"11029_CR3","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1097\/MJT.0000000000000853","volume":"27","author":"S Wakefield","year":"2020","unstructured":"Wakefield S, Aligeti M, Rachamallu V, Baronia R, Aynampudi R, Parmar A, Peterson P, Masodkar K. Metabolic Monitoring of Child and Adolescent Patients on Atypical Antipsychotics by Psychiatrists and Primary Care Providers. Am J Ther. 2020;27(5):e425\u201330.","journal-title":"Am J Ther"},{"issue":"13","key":"11029_CR4","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.2147\/NDT.S113099","volume":"22","author":"M Dayabandara","year":"2017","unstructured":"Dayabandara M, Hanwella R, Ratnatunga S, Seneviratne S, Suraweera C, de Silva VA. Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. Neuropsychiatr Dis Treat. 2017;22(13):2231\u201341.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"11029_CR5","doi-asserted-by":"crossref","unstructured":"Rettew DC, Greenblatt J, Kamon J, Neal D, Harder V, Wasserman R, Berry P, MacLean CD, Hogue N, McMains W. Antipsychotic Medication Prescribing in Children Enrolled in Medicaid. Pediatrics. 2015;135(4):658\u201365.","DOI":"10.1542\/peds.2014-2260"},{"issue":"12","key":"11029_CR6","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1176\/appi.ps.201300574","volume":"65","author":"B Saloner","year":"2014","unstructured":"Saloner B, Matone M, Kreider AR, et al. Second-generation antipsychotic use among stimulant-using children, by organization of Medicaid mental health. Psychiatr Serv. 2014;65(12):1458\u201364.","journal-title":"Psychiatr Serv"},{"issue":"6","key":"11029_CR7","doi-asserted-by":"publisher","first-page":"e1459","DOI":"10.1542\/peds.2010-2970","volume":"128","author":"S Dosreis","year":"2011","unstructured":"Dosreis S, Yoon Y, Rubin DM, Riddle MA, Noll E, Rothbard A. Antipsychotic treatment among youth in foster care. Pediatrics. 2011;128(6):e1459\u201366.","journal-title":"Pediatrics"},{"key":"11029_CR8","unstructured":"Christian R, Saavedra L, Gaynes BN, et al. Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Feb. (Future Research Needs Papers, No. 13.) Appendix A, Tables of FDA-Approved Indications for First- and Second-Generation Antipsychotics."},{"issue":"1","key":"11029_CR9","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s12888-021-03533-3","volume":"21","author":"M Candon","year":"2021","unstructured":"Candon M, Shen S, Fadeyibi O, Smith JL, Rothbard A. Trends in antipsychotic prescribing for approved and unapproved indications to Medicaid-enrolled youth in Philadelphia, Pennsylvania between 2014 and 2018. BMC Psychiatry. 2021;21(1):524.","journal-title":"BMC Psychiatry"},{"key":"11029_CR10","doi-asserted-by":"crossref","unstructured":"Sohn M, Moga DC, Blumenschein K, Talbert J. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States [published correction appears in Medicine (Baltimore). 2016;95(28):e0916.","DOI":"10.1097\/MD.0000000000003784"},{"issue":"5 Suppl","key":"11029_CR11","doi-asserted-by":"publisher","first-page":"S68","DOI":"10.1016\/j.acap.2014.05.009","volume":"14","author":"E Kealey","year":"2014","unstructured":"Kealey E, Scholle SH, Byron SC, Hoagwood K, Leckman-Westin E, Kelleher K, Finnerty M. Quality concerns in antipsychotic prescribing for youth: a review of treatment guidelines. Acad Pediatr. 2014;14(5 Suppl):S68-75.","journal-title":"Acad Pediatr"},{"key":"11029_CR12","unstructured":"Substance\u00a0Abuse\u00a0and Mental\u00a0Health\u00a0Services\u00a0Administration:\u00a0Guidance\u00a0on Strategies\u00a0to Practice\u00a0in\u00a0Antipsychotic\u00a0Prescribing\u00a0for\u00a0Children\u00a0and\u00a0Adolescents.\u00a0HHS\u00a0Publication\u00a0No.PEP19\u2010 ANTIPSYCHOTIC\u2010BP.\u00a0Rockville."},{"issue":"9","key":"11029_CR13","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1001\/jama.2015.0763","volume":"313","author":"I Schmid","year":"2015","unstructured":"Schmid I, Burcu M, Zito JM. Medicaid prior authorization policies for pediatric use of antipsychotic medications. JAMA. 2015;313(9):966\u20138.","journal-title":"JAMA"},{"issue":"1","key":"11029_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaac.2016.10.005","volume":"56","author":"GA Edelsohn","year":"2017","unstructured":"Edelsohn GA, Karpov I, Parthasarathy M, Hutchison SL, Castelnovo K, Ghuman J, Schuster JM. Trends in antipsychotic prescribing in medicaid-eligible youth. J Am Acad Child Adolesc Psychiatry. 2017;56(1):59\u201366.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"11029_CR15","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/pds.5032","volume":"29","author":"O Spence","year":"2020","unstructured":"Spence O, Reeves G, dosReis S. Spillover effects of state Medicaid antipsychotic prior authorization policies in US commercially insured youth. Pharmacoepidemiol Drug Saf. 2020;29(9):1064\u201371.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"11029_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jaac.2019.04.022","volume":"59","author":"TI Mackie","year":"2020","unstructured":"Mackie TI, Cook S, Crystal S, Olfson M, Akincigil A. Antipsychotic Use Among Youth in Foster Care Enrolled in a Specialized Managed Care Organization Intervention. J Am Acad Child Adolesc Psychiatry. 2020;59(1):166-176.e3.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"11029_CR17","doi-asserted-by":"crossref","unstructured":"Jamtvedt G, Young JM, Kristoffersen DT, Thomson O'Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2003;19(2):CD000259.","DOI":"10.1002\/14651858.CD000259"},{"issue":"3","key":"11029_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1377\/hlthaff.2021.01407","volume":"41","author":"AS Navathe","year":"2022","unstructured":"Navathe AS, Liao JM, Yan XS, Delgado MK, Isenberg WM, Landa HM, Bond BL, Small DS, Rareshide CAL, Shen Z, Pepe RS, Refai F, Lei VJ, Volpp KG, Patel MS. The effect of clinician feedback interventions on opioid prescribing. Health Aff (Millwood). 2022;41(3):424\u201333.","journal-title":"Health Aff (Millwood)"},{"key":"11029_CR19","doi-asserted-by":"crossref","unstructured":"Candon M, Xue L, Shen L, Cole E, Donohue J, Rothbard A. The impact of opioid prescribing report cards in medicaid. J Manag Care Special Pharm. 2022;28(8):862\u201370.","DOI":"10.18553\/jmcp.2022.28.8.862"},{"issue":"6","key":"11029_CR20","doi-asserted-by":"publisher","first-page":"e1296","DOI":"10.1093\/cid\/ciab256","volume":"73","author":"N Daneman","year":"2021","unstructured":"Daneman N, Lee SM, Bai H, Bell CM, Bronskill SE, Campitelli MA, Dobell G, Fu L, Garber G, Ivers N, Lam JMC, Langford BJ, Laur C, Morris A, Mulhall C, Pinto R, Saxena FE, Schwartz KL, Brown KA. Population-wide peer comparison audit and feedback to reduce antibiotic initiation and duration in long-term care facilities with embedded randomized controlled trial. Clin Infect Dis. 2021;73(6):e1296\u2013304.","journal-title":"Clin Infect Dis."},{"issue":"1","key":"11029_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s43058-020-00013-9","volume":"25","author":"NM Ivers","year":"2020","unstructured":"Ivers NM, Taljaard M, Giannakeas V, Reis C, Mulhall CL, Lam JMC, Burchell AN, Lebovic G, Bronskill SE. Effectiveness of confidential reports to physicians on their prescribing of antipsychotic medications in nursing homes. Implement Sci Commun. 2020;25(1):30.","journal-title":"Implement Sci Commun"},{"issue":"1","key":"11029_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5498\/wjp.v8.i1.27","volume":"8","author":"S Gnanavel","year":"2018","unstructured":"Gnanavel S, Hussain S. Audit of physical health monitoring in children and adolescents receiving antipsychotics in neurodevelopmental clinics in Northumberland. World J Psychiatry. 2018;8(1):27\u201332.","journal-title":"World J Psychiatry"},{"issue":"3","key":"11029_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1365-2753.2008.01032.x","volume":"15","author":"A Wheeler","year":"2009","unstructured":"Wheeler A, Humberstone V, Robinson E, Sheridan J, Joyce P. Impact of audit and feedback on antipsychotic prescribing in schizophrenia. J Eval Clin Pract. 2009;15(3):441\u201350.","journal-title":"J Eval Clin Pract"},{"issue":"9","key":"11029_CR24","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1176\/appi.ps.201700536","volume":"69","author":"MF Brunette","year":"2018","unstructured":"Brunette MF, Cotes RO, de Nesnera A, McHugo G, Dzebisashvili N, Xie H, Bartels SJ. Use of academic detailing with audit and feedback to improve antipsychotic pharmacotherapy. Psychiatr Serv. 2018;69(9):1021\u20138.","journal-title":"Psychiatr Serv."},{"issue":"6","key":"11029_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1176\/appi.ps.202000155","volume":"72","author":"T Soda","year":"2021","unstructured":"Soda T, Richards J, Gaynes BN, Cueva M, Laux J, McClain C, Frische R, Lindquist LK, Cuddeback GS, Jarskog LF. Systematic quality improvement and metabolic monitoring for individuals taking antipsychotic drugs. Psychiatr Serv. 2021;72(6):647\u201353.","journal-title":"Psychiatr Serv."},{"issue":"6","key":"11029_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1192\/bjp.bp.107.042895","volume":"192","author":"C Paton","year":"2008","unstructured":"Paton C, Barnes TR, Cavanagh MR, Taylor D, Lelliott P, POMH-UK project team. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing. Br J Psychiatry. 2008;192(6):435\u20139.","journal-title":"Br J Psychiatry."},{"issue":"1","key":"11029_CR27","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1186\/s12913-021-06645-4","volume":"21","author":"AH Glenng\u00e5rd","year":"2021","unstructured":"Glenng\u00e5rd AH, Anell A. The impact of audit and feedback to support change behaviour in healthcare organisations - a cross-sectional qualitative study of primary care centre managers. BMC Health Serv Res. 2021;21(1):663.","journal-title":"BMC Health Serv Res"},{"key":"11029_CR28","unstructured":"US Department of Health & Human Services, Administration for Children & Families. Child Welfare Information Gateway. Taken from https:\/\/www.childwelfare.gov\/topics\/outofhome\/foster-care\/. August 17, 2021."},{"key":"11029_CR29","unstructured":"Pew Charitable Trust. Philadelphia: The State of the City. Taken from https:\/\/www.pewtrusts.org\/-\/media\/assets\/2021\/04\/philadelphia-2021-state-of-the-city.pdf. August 17, 2021."},{"issue":"2","key":"11029_CR30","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3121\/cmr.2013.1113","volume":"11","author":"SJ Rolnick","year":"2013","unstructured":"Rolnick SJ, Pawloski PA, Hedblom BD, Asche SE, Bruzek RJ. Patient characteristics associated with medication adherence. Clin Med Res. 2013;11(2):54\u201365.","journal-title":"Clin Med Res"},{"key":"11029_CR31","volume-title":"Psychotropic Medication Use by Pennsylvania Children in Foster Care and Enrolled in Medicaid: An Analysis of Children Ages 3\u201318 Years","author":"M Matone","year":"2015","unstructured":"Matone M, Zlotnik S, Miller D, Kreider A, Rubin D, Noonan K. Psychotropic Medication Use by Pennsylvania Children in Foster Care and Enrolled in Medicaid: An Analysis of Children Ages 3\u201318 Years. Philadelphia: PolicyLab at the Children\u2019s Hospital of Philadelphia; 2015."},{"key":"11029_CR32","unstructured":"National Committee for Quality Assurance. Use of First-line Psychosocial Care for Children and Adolescents on Antipsychotics. Taken from\u00a0https:\/\/www.ncqa.org\/hedis\/measures\/use-of-first-line-psychosocial-care-for-children-andadolescents-on-anti-psychotics\/#:~:text=Why%20It%20Matters,are%20considered%20first%2Dline%20treatment \u00a0on 2\/29\/24."},{"key":"11029_CR33","unstructured":"Community Behavioral Health. Provider Lab Tip Sheet. Taken from https:\/\/cbhphilly.org\/wp-content\/uploads\/2023\/12\/CBH_ICP_Tip-Sheets_Providers_Lab.pdf on 2\/29\/24."},{"issue":"4","key":"11029_CR34","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1177\/1078390317752444","volume":"24","author":"EL Featherston","year":"2018","unstructured":"Featherston EL, Dihigo S, Gilder RE. Improving Adherence to Atypical Antipsychotic Agent Screening Guidelines in Pediatric Patients: A Quality Improvement Project Within an Integrated Community Mental Health Setting. J Am Psychiatr Nurses Assoc. 2018;24(4):352\u20139.","journal-title":"J Am Psychiatr Nurses Assoc."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11029-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-024-11029-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-024-11029-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T10:09:56Z","timestamp":1714730996000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-024-11029-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["11029"],"URL":"https:\/\/doi.org\/10.1186\/s12913-024-11029-5","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,3]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Boards of the City of Philadelphia and the University of Pennsylvania, who also approved a waiver of informed consent on the grounds that (a) the research involves no more than minimal risk to participants; (b) the waiver will not adversely affect the rights and welfare of participants; and (c) this research, which was retrospective and used secondary data, could not be practically carried out without the waiver. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Candon, Ms. Shen, and Dr. Rothbard receive funding from Community Behavioral Health and the Department of Behavioral Health and Intellectual Disability Services for program evaluation. Dr. Everett, Dr. Demp, Dr. Weingartner, and Dr. Fadeyibi are employed by Community Behavioral Health. Ms. Reed did not receive funding from Community Behavioral Health or the Department of Behavioral Health and Intellectual Disability Services. There are no other conflicts of interest to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"574"}}